> Videos > Pluvicto in Metastatic Hormone-Sensitive Prostate Cancer

Pluvicto in Metastatic Hormone-Sensitive Prostate Cancer

Patients with prostate cancer that has spread now have a new treatment option to consider.

The FDA has expanded its approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include metastatic hormone-sensitive prostate cancer (mHSPC). This type of prostate cancer is also called androgen pathway modulation-naïve or sensitive (mAPMN/S).

PCF’s Dr. Phillip Koo speaks with leading experts to explain what this could mean for you or a loved one. You’ll learn about:

  • How radioligand therapy works
  • How you know if you may be eligible
  • Patient experience with treatment, side effects, and radiation safety
  • How you and your doctor can consider Pluvicto in the landscape of treatment options for mHSPC
  • Questions to ask your doctor